 |
42 Diseases |  |
114 Trials |
|
114 Trials |  |
1654 News |  |
| «12...19202122232425262728293031» |
- | Mekinist (trametinib) / Novartis, BeiGene
New P2/3 trial: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (clinicaltrials.gov) - Mar 31, 2014
P2/3, N=250, Recruiting, Sponsor: National Cancer Institute (NCI)
- eprenetapopt (APR-246) / Aprea
New P1/2 trial: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 (clinicaltrials.gov) - Mar 26, 2014
P1/2, N=0, Recruiting, Sponsor: Aprea AB
- pegylated liposomal doxorubicin / Generic mfg., nintedanib / Generic mfg.
Trial suspension, Combination therapy: Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer (clinicaltrials.gov) - Mar 13, 2014
P1/2, N=41, Suspended, Sponsor: Hoosier Oncology Group
Recruiting --> Suspended
- | New P1 trial, Metastases: A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer (clinicaltrials.gov) - Mar 5, 2014
P1, N=42, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- carboplatin / Generic mfg.
Trial completion: Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors (clinicaltrials.gov) - Mar 5, 2014
P2, N=41, Completed, Sponsor: AGO Study Group
Recruiting --> Suspended Active, not recruiting --> Completed
- ||| lifastuzumab vedotin (DNIB0600A) / Roche
Trial initiation date: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (clinicaltrials.gov) - Feb 23, 2014
P2, N=92, Recruiting, Sponsor: Genentech
Active, not recruiting --> Completed Initiation date: Nov 2013 --> Feb 2014
- || pegylated liposomal doxorubicin / Generic mfg., daunorubicin / Generic mfg.
New P3 trial: Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia: (clinicaltrials.gov) - Feb 23, 2014
P3, N=200, Recruiting, Sponsor: Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.
- |||| pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Metastases: Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients (clinicaltrials.gov) - Feb 22, 2014
P4, N=154, Completed, Sponsor: Spanish Breast Cancer Research Group
Initiation date: Nov 2013 --> Feb 2014 Recruiting --> Completed
- ||||||| Telcyta (canfosfamide) / MabVax
Trial completion, Combination therapy: TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=244, Completed, Sponsor: Telik
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P3, N=225, Completed, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ThermoDox (lyso-thermosensitive liposomal doxorubicin) / Imunon
Trial completion: Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: Celsion
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Telcyta (canfosfamide) / MabVax
Trial completion: TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=440, Completed, Sponsor: Telik
Recruiting --> Completed No longer recruiting --> Completed
- | Telcyta (canfosfamide) / MabVax
Trial completion, Combination therapy: TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=28, Completed, Sponsor: Telik
No longer recruiting --> Completed No longer recruiting --> Completed
- | DaunoXome (liposomal daunorubicin) / SOBI, Galen
Trial completion: Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Roswell Park Cancer Institute
No longer recruiting --> Completed Not yet recruiting --> Completed
- | Herceptin (trastuzumab) / Roche
Trial completion, Metastases: Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: New York University School of Medicine
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1, N=10, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Metastases: Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=76, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed No longer recruiting --> Completed
- | pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Metastases: Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Gynecologic Oncology Group
No longer recruiting --> Completed No longer recruiting --> Completed
- | pegylated liposomal doxorubicin / Generic mfg.
Trial completion, Metastases: Chemotherapy in Treating Patients With Sarcoma of the Uterus (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Gynecologic Oncology Group
No longer recruiting --> Completed No longer recruiting --> Completed
- | Myocet (non-pegylated liposomal doxorubicin) / Teva, Sopherion, Herceptin (trastuzumab) / Roche
Trial completion, Metastases: Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=45, Completed, Sponsor: Georgetown University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Liposomal Doxorubicin in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=10, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=38, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=48, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Amdray (valspodar) / Novartis
Trial completion, IO biomarker, Metastases: Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers (clinicaltrials.gov) - Feb 19, 2014
P1, N=14, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Completed
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment change, Metastases: ICEBERG 3: Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=125, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Completed N=97 --> 125
- pegylated liposomal doxorubicin / Generic mfg.
Enrollment open, BRCA Biomarker, Metastases: Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy (clinicaltrials.gov) - Jan 16, 2014
P2, N=50, Recruiting, Sponsor: University of Arizona
N=97 --> 125 Not yet recruiting --> Recruiting
- | Trial completion: CALYPSO: Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (clinicaltrials.gov) - Jan 8, 2014
P3, N=976, Completed, Sponsor: ARCAGY/ GINECO GROUP
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||| motolimod (VTX 2337) / BMS
Enrollment change, Combination therapy: VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Jan 7, 2014
P2, N=290, Active, not recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
Active, not recruiting --> Completed N=210 --> 290
- Actemra IV (tocilizumab) / Roche, JW Pharma, ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: PITCH: Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer (clinicaltrials.gov) - Jan 5, 2014
P1/2, N=21, Completed, Sponsor: Leiden University Medical Center
N=210 --> 290 Recruiting --> Completed
- Herceptin (trastuzumab) / Roche
Trial termination, Metastases: Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy (clinicaltrials.gov) - Dec 22, 2013
P2, N=24, Terminated, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Recruiting --> Completed Active, not recruiting --> Terminated; Caelyx was not available anymore
- Herceptin (trastuzumab) / Roche
Enrollment change, Metastases: Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy (clinicaltrials.gov) - Dec 22, 2013
P2, N=24, Terminated, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Active, not recruiting --> Terminated; Caelyx was not available anymore N=30 --> 24
- pegylated liposomal doxorubicin / Generic mfg., capecitabine / Generic mfg.
Trial initiation date: Testing the Effectiveness of Henna on Managing PPE (clinicaltrials.gov) - Dec 19, 2013
P=N/A, N=80, Not yet recruiting, Sponsor: Cyprus University of Technology
N=30 --> 24 Initiation date: Mar 2013 --> Mar 2014
- pegylated liposomal doxorubicin / Generic mfg., capecitabine / Generic mfg.
Enrollment change: Testing the Effectiveness of Henna on Managing PPE (clinicaltrials.gov) - Dec 19, 2013
P=N/A, N=80, Not yet recruiting, Sponsor: Cyprus University of Technology
Initiation date: Mar 2013 --> Mar 2014 N=250 --> 80
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Trial completion: PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=70, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=250 --> 80 Recruiting --> Completed
- ||||| trebananib (AMG 386) / Amgen
Enrollment change: AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) (clinicaltrials.gov) - Dec 4, 2013
P3, N=223, Active, not recruiting, Sponsor: Amgen
Recruiting --> Completed N=380 --> 223
- ||||| trebananib (AMG 386) / Amgen
Enrollment closed: AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) (clinicaltrials.gov) - Dec 4, 2013
P3, N=223, Active, not recruiting, Sponsor: Amgen
N=380 --> 223 Recruiting --> Active, not recruiting
- | Telcyta (canfosfamide) / MabVax
Trial termination, Combination therapy: ASSIST-5: Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer (clinicaltrials.gov) - Nov 25, 2013
P3, N=244, Terminated, Sponsor: Telik
Recruiting --> Active, not recruiting Completed --> Terminated; Business reasons
- ||||| lifastuzumab vedotin (DNIB0600A) / Roche
New P2 trial: A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) (clinicaltrials.gov) - Nov 21, 2013
P2, N=92, Recruiting, Sponsor: Genentech
- pegylated liposomal doxorubicin / Generic mfg.
New P2 trial, BRCA Biomarker, Metastases: Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy (clinicaltrials.gov) - Nov 19, 2013
P2, N=50, Recruiting, Sponsor: University of Arizona
- | Avastin (bevacizumab) / Roche
Trial initiation date: ENGOT-ov 17: Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer (clinicaltrials.gov) - Nov 12, 2013
P3, N=400, Recruiting, Sponsor: National Cancer Institute, Naples
Completed --> Terminated; Business reasons Initiation date: Mar 2013 --> Nov 2013
- | Avastin (bevacizumab) / Roche
Enrollment open: ENGOT-ov 17: Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer (clinicaltrials.gov) - Nov 12, 2013
P3, N=400, Recruiting, Sponsor: National Cancer Institute, Naples
Initiation date: Mar 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- Enrollment closed, Combination therapy, Metastases: BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (clinicaltrials.gov) - Nov 12, 2013
P1, N=24, Active, not recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- lapatinib / Generic mfg.
Trial completion, Combination therapy, Metastases: Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Nov 5, 2013
P1, N=23, Completed, Sponsor: Northwestern University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial initiation date: MYLY: Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine. (clinicaltrials.gov) - Nov 4, 2013
P2, N=25, Recruiting, Sponsor: University Hospital, Brest
Active, not recruiting --> Completed Initiation date: May 2013 --> Oct 2013
- Enrollment open: MYLY: Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine. (clinicaltrials.gov) - Nov 4, 2013
P2, N=25, Recruiting, Sponsor: University Hospital, Brest
Initiation date: May 2013 --> Oct 2013 Not yet recruiting --> Recruiting
- |||||| Avastin (bevacizumab) / Roche
Enrollment open: ENGOT ov-18: Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Nov 3, 2013
P3, N=654, Recruiting, Sponsor: AGO Research GmbH
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- ||||| Trial initiation date, Monotherapy, Metastases: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - Oct 31, 2013
P3, N=670, Recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Recruiting Initiation date: Jun 2013 --> Oct 2013
- Ninlaro (ixazomib) / Takeda
Enrollment open: Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - Oct 6, 2013
P1, N=18, Recruiting, Sponsor: Ehab L Atallah
Initiation date: Jun 2013 --> Oct 2013 Not yet recruiting --> Recruiting
- Decadron (dexamethasone) / Merck (MSD)
Trial completion, IO biomarker: Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies (clinicaltrials.gov) - Sep 29, 2013
P2, N=13, Completed, Sponsor: Milton S. Hershey Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed